Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Drug Profile

Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Alternative Names: AAV-ZFP-VEGF; Ad-ZFP-VEGF; AdV-ZFP-VEGF; ZFP TF ATV; ZFP TF therapeutics - Sangamo

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo BioSciences; Sangamo Therapeutics
  • Class Transcription factors; Zinc finger DNA binding proteins
  • Mechanism of Action Genetic transcription modulators; Glial cell line-derived neurotrophic factor agonists; Nav1.8 voltage-gated sodium channel inhibitors; Neuron stimulants; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuropathic pain; Parkinson's disease
  • Discontinued Age-related macular degeneration; Cancer

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 12 Oct 2012 Preclinical development is ongoing in USA
  • 04 Mar 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top